Avantor vs Bio-Rad Laboratories

Avantor (AVTR), health care, and Bio-Rad Laboratories (BIO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Avantor is worth $10.3B on the stock market and Bio-Rad Laboratories $9.6B: Avantor is valued at 7% more. Avantor trades at 30.4 times earnings and Bio-Rad Laboratories at 9.5; operating margins in their latest fiscal years were -3.76% and 1.83%. Over the past year Avantor's share price has moved +37.5% and Bio-Rad Laboratories's +17.1%.

Key facts

Avantor market value
$10.3B
Bio-Rad Laboratories market value
$9.6B
Avantor P/E
30.4
Bio-Rad Laboratories P/E
9.5
Avantor revenue
$6.6BFY to 2025-12-31
Bio-Rad Laboratories revenue
$2.6BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Avantor vs Bio-Rad Laboratories: every measure side by side
Measure Avantor Bio-Rad Laboratories
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$10.3Bhigher$9.6Blower
Revenue$6.6Bhigher$2.6Blower
Earnings-$530.2Mlower$759.9Mhigher
Employees13,500higher7,450lower
Total assets$11.8Bhigher$10.6Blower
Valuation
P/E30.4higher9.5lower
P/S1.6lower3.7higher
P/B1.8higher1.3lower
Dividend yield0.00%0.00%
Profitability
Operating margin-3.76%lower1.83%higher
Balance sheet
Net assets$5.6Blower$7.5Bhigher
Total liabilities$6.2Bhigher$3.1Blower
Total debt$3.9Bhigher$1.2Blower
Cash on hand$365.4Mlower$529.8Mhigher
Price change
Today-0.91%lower-0.57%higher
1 year+37.5%higher+17.1%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Avantor / Bio-Rad Laboratories). Who owns AVTR · Who owns BIO

Further comparisons

Learn

Questions and answers

Which is bigger, Avantor or Bio-Rad Laboratories?

By market value, Avantor is the larger: $10.3B against $9.6B for Bio-Rad Laboratories. By revenue in its latest fiscal year, Avantor is the larger: $6.6B against $2.6B for Bio-Rad Laboratories.

Which has the higher P/E ratio?

Avantor: 30.4, against 9.5 for Bio-Rad Laboratories. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Bio-Rad Laboratories: 1.83%, against -3.76% for Avantor. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Avantor: $3.9B, against $1.2B for Bio-Rad Laboratories. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Avantor and Bio-Rad Laboratories?

In their latest 13F filings, Steven Romick holds both.

Cite this page

Funkfolio, “Avantor vs Bio-Rad Laboratories”, data as of 17 November 2026. https://funkfolio.com/compare/avtr-vs-bio

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.